National perspectives on the CJEU Bayer decision

This month in Synapse

National perspectives on the CJEU Bayer decision

Our European team looks at what the CJEU decision in case C-688/17 may mean for national practice.

Medical devices and managing product liability risks

We look at medical device product liability, starting with an incident report to a regulator and following the potential issues that a manufacturer might face.

Clash of IP and competition to pharma's detriment? The CJEU's decision in theGSK case

Paolo Parmigiano and Barbora Dubanská explore the latest CJEU judgment in relation to pay-for-delay settlement agreements.

To Neurim or not to Neurim, that is the question

Anja Lunze examines what the Opinion of Advocate General Giovanni Pitruzella says concerning supplementary protection certificates.

Changes in the industrial property law of Poland

Kalina Skwiecińska and Agnieszka Sztoldman provide an overview of the changes to Polish industrial property law that recently came into effect.

Pricing: highlights of the J.P. Morgan Healthcare Conference

Barbora Dubanská reports on what the conference had to say about a major healthcare hot topic – drug pricing.

Patents diary: February 2020

A CRISPR Cas9 patent has its priority rejected by the Technical Board of Appeal, and there is a rare and successful application of the Crown use defence to infringement in the UK.